Neurological Injury
Neurological injury, the broad family that includes stroke, traumatic brain injury, oxygen-deprivation injury and spinal cord injury, is the least-developed area of psychedelic research on this site, and the one where the gap between hope and evidence is widest. As with brain injury generally, almost none of the work is about repairing damaged tissue; it is about the depression, anxiety, post-traumatic stress and lost functioning that follow, and, in animals, about whether psychedelics can nudge the brain’s own recovery. The single human result with real weight sits in the traumatic brain injury sub-topic (an uncontrolled magnesium-ibogaine study in veterans). Everywhere else the evidence is preclinical or very early, and ketamine’s main role is in acute intensive care, not psychedelic therapy.
Data updated
Key Insights
- 1
This is an umbrella topic for acquired, structural damage to the nervous system: stroke, traumatic brain injury, oxygen-deprivation (hypoxic) injury and spinal cord injury. Its one sub-topic with a genuine human signal is traumatic brain injury, which has its own page.
- 2
As with brain injury generally, the research is about the after-effects (depression, anxiety, post-traumatic stress, lost functioning) and, in animal studies, about aiding the brain’s own recovery, not about repairing the injury. No psychedelic is shown to heal nervous-system damage.
- 3
The headline human result in the whole category is the uncontrolled magnesium-ibogaine study in blast-injured veterans, covered on the traumatic brain injury page. For stroke, hypoxic and spinal injury specifically, the evidence is essentially preclinical.
- 4
The mechanistic rationale (psychedelics promote neuroplasticity and reduce neuroinflammation) is appealing after an injury, and a few small, early trials are exploring adjacent conditions such as functional neurological disorder. But none of this is controlled human evidence of benefit for neurological injury.
- 5
Ketamine appears throughout this field mainly as an acute intensive-care drug (sedation, managing pressure in the skull, disorders of consciousness), which is not psychedelic therapy. No psychedelic is approved for any neurological injury.
By the numbers
- 19
- Trials tracked
- 29
- Papers tracked
- 1,370
- Trial participants
as of June 2026
as of June 2026
as of June 2026
What is Neurological Injury?
Neurological injury is a broad category covering acquired, structural damage to the nervous system: stroke (where blood supply to part of the brain is lost), traumatic brain injury, hypoxic or anoxic injury (where the brain is deprived of oxygen, for example after cardiac arrest), and spinal cord injury. Together these are among the largest causes of long-term disability in the world. Reviews of psychedelics for acquired brain injury set out both the scale of the problem and the early state of the science[1].
The same distinction that governs the brain-injury research applies across this whole family, and it is the key to reading the page honestly: psychedelics are not shown to repair damaged neural tissue. What the research actually targets is twofold, the disabling psychiatric and functional after-effects of injury (depression, anxiety, post-traumatic stress, cognitive and motor problems), and, mostly in animal models, the brain’s own capacity for plastic recovery. Claims that a psychedelic "treats neurological injury" almost always mean one of those two things, not structural healing.
This is an umbrella page, and it is deliberately high-level, because the evidence is thin and concentrated. The one sub-area with a real human signal is traumatic brain injury, which has its own dedicated traumatic brain injury page; the closely related question of progressive, degenerative conditions is covered under neurocognitive disorders. Here we summarise the family as a whole and are candid about how little, beyond TBI, has actually been tested in people.
Current Treatments
Across these injuries the established approach is broadly similar: acute medical care to limit further damage (restoring blood flow in stroke, managing pressure and oxygen after brain injury, stabilising the spine), followed by intensive, long-term rehabilitation, physical, occupational, cognitive and speech therapy, that does the real work of recovery. There is no drug that reverses the injury itself, and rehabilitation, though effective, is slow and rarely complete.
The unmet need has two faces. The first is recovery itself: many people plateau with lasting deficits that no current treatment can shift. The second is the psychiatric burden, post-stroke depression, the anxiety and post-traumatic stress that follow brain injury, the demoralisation of life-changing disability, which is common, undertreated and a major driver of poor outcomes. Psychedelic research is aimed almost entirely at this second face, the mental-health after-effects, with the hope (so far mostly preclinical) that it might one day touch the first. Everything below is investigational.
This report summarises what Blossom’s database shows about psychedelics and neurological injury, the broad family that includes stroke, traumatic brain injury, oxygen-deprivation injury and spinal cord injury. It is the least-developed topic in this collection, and an honest account is mostly an account of absence: a great deal of mechanistic promise, one striking but uncontrolled human result confined to traumatic brain injury, and almost no controlled human evidence anywhere else.
A note before the evidence
This page is a research summary, not medical advice, and nothing here is a treatment recommendation. No psychedelic is approved for, or shown to repair, any neurological injury. One of the drugs discussed, ibogaine, can cause fatal heart-rhythm disturbances and is mostly used in unregulated overseas settings. Established care, acute medical treatment plus long-term rehabilitation, and evidence-based treatment of the depression and anxiety that follow injury, is the foundation and should not be set aside in favour of experimental options. If you or someone you care for is recovering from a neurological injury, please work with the clinical team.
A word on scope and numbers. Blossom tracks only a few dozen papers and trials here, and they are unusually mixed: mechanism reviews, animal studies, ketamine used as an intensive-care anaesthetic, and work that really belongs to the traumatic brain injury sub-topic. The amount of controlled human evidence testing a psychedelic as a treatment for neurological injury is, in practice, close to zero. Read the counts as breadth of interest in a young field, not as depth of proof.
One umbrella, very uneven evidence
The first thing to understand is that "neurological injury" is not one evidence base but several, of wildly different maturity. Traumatic brain injury has attracted real human research and has its own page. Stroke, the other huge category, has essentially no psychedelic clinical trials, only preclinical work and the general interest in post-stroke depression. Hypoxic and spinal cord injuries have less still. So statements about "psychedelics for neurological injury" almost always rest on TBI data or on animal studies, and stretching them across the whole family is exactly the kind of overreach this page exists to flag.
The unifying idea, and the honest boundary, is the same as on the brain-injury page: this research is about the after-effects of injury and about the brain’s plastic recovery, not about repairing damaged tissue. A stroke kills neurons; a psychedelic does not bring them back. What it might plausibly do, on current thinking, is ease the depression and anxiety that follow, and perhaps support the rehabilitation process by enhancing plasticity. Both are hypotheses worth testing, and neither is established.
The one human signal, and where it lives
The only result in this family with real human weight is the magnesium-ibogaine work in veterans, and it belongs to traumatic brain injury specifically. An uncontrolled study reported large improvements in PTSD, depression, anxiety and functioning in special-operations veterans with blast-related TBI[1]. It is genuinely striking, and genuinely limited: observational, self-selected, conducted at an overseas clinic, and reliant on a drug that can stop the heart. The full account and its caveats are on the traumatic brain injury page, because it would be misleading to present a single uncontrolled TBI study as evidence for "neurological injury" in general.
There are fainter echoes elsewhere, such as a case series of iboga microdosing in post-concussive and hypoxic brain injury[2] and observational reports of psilocybin retreats improving mental health in veterans with injury histories[3]. These are worth knowing and easy to over-read: they are uncontrolled, self-selected and small. They point toward trials; they do not stand in for them.
The mechanistic promise, and its limits
The reason serious researchers take this field seriously despite the thin clinical evidence is the biology. Classic psychedelics reliably promote neuroplasticity, the growth and rewiring of neural connections, and reduce neuroinflammation, and reviews of psychedelics for acquired brain injury lay out in detail why those effects are attractive in the aftermath of an injury[4], when the brain is trying to reorganise around damage. In animal models of brain injury, these effects translate into measurable improvements.
The limit is the gap between a mouse and a person. Many interventions improve recovery in animal injury models and then fail in human trials, because the human brain, the injuries, and the outcomes that matter are all more complex. So the neuroplasticity story is a strong reason to run trials, not a substitute for their results. The most concrete human steps so far are in adjacent conditions, early trials of psilocybin-assisted approaches in functional neurological disorder, for instance, rather than in the core injuries of stroke or spinal damage.
Ketamine: an acute-care drug that is mostly off-topic
A large share of the "psychedelic" research that appears under neurological injury is really about ketamine in intensive care, and it is worth separating out. Ketamine is a valuable acute anaesthetic in severe brain injury because it works fast and does not suppress breathing, and it is studied for managing intracranial pressure and even for its physiological effects and outcomes after brain injury[5], as well as, experimentally, for waking patients from disorders of consciousness. None of that is psychedelic therapy; it is mainstream neurocritical care that happens to use the same molecule.
The genuinely on-topic ketamine question, using its rapid antidepressant effect for the mood consequences of injury such as post-stroke depression, is real but early, with only small trials so far. Keeping these two ketamines apart matters: conflating the well-established intensive-care use with the speculative sequelae-treatment use would make the evidence base look far stronger than it is.
Reading this honestly
So where does neurological injury sit? It is the widest and emptiest of these pages: a family of devastating, common conditions, a compelling biological rationale, and almost no controlled human evidence that psychedelics help any of them. The one striking human result is confined to traumatic brain injury, is uncontrolled, and depends on a dangerous drug. Everywhere else, stroke, hypoxic injury, spinal cord injury, the case rests on animal studies and hope. Reviewers in the area consistently frame it as promising but preliminary[6], and that is the right note. For people living with the aftermath of a neurological injury, the truthful message is that psychedelics are an active and genuinely interesting area of research, especially for the psychiatric after-effects, and that they are not, today, a treatment for the injury or a substitute for the rehabilitation and mental-health care that remain the real foundations of recovery.
Psychedelic Effect Matrix
Compound efficacy and evidence levels for Neurological Injury.
| Compound | Magnitude | Evidence | Consistency |
|---|---|---|---|
| Ibogaine The only compound with a human signal in this family, and it is concentrated in traumatic brain injury: an uncontrolled magnesium-ibogaine study in blast-injured veterans (see the TBI page). It targets the psychiatric after-effects, not the injury, and ibogaine carries a fatal cardiac-arrhythmia risk. No evidence in stroke, hypoxic or spinal injury. | Small | Low | Low |
| Psilocybin No controlled human evidence in neurological injury. The appeal is mechanistic (neuroplasticity, reduced inflammation in animal models) plus early observational data in veterans and small trials in adjacent conditions such as functional neurological disorder. A plausible hypothesis, not a demonstrated treatment. | Small | Very Low | Low |
| Ketamine Mostly a separate, acute-care story: ketamine is used in the intensive-care management of severe brain injury (sedation, intracranial pressure, disorders of consciousness), which is not psychedelic therapy. Its use for the depression that follows injury (e.g. post-stroke depression) is only beginning to be trialled. | Small | Low | Low |
Ibogaine and Neurological Injury
Ibogaine is the only compound that has produced a striking human result anywhere in this family, and that result is specific to traumatic brain injury, not neurological injury broadly. An uncontrolled study of magnesium-ibogaine in special-operations veterans with blast-related TBI reported large improvements in PTSD, depression, anxiety and functioning[1]. Because it belongs to the TBI sub-topic, the detail, and the important caveats about its observational design and ibogaine’s cardiac danger, live on the traumatic brain injury page.
Beyond TBI, ibogaine in neurological injury is barely studied. There is early, anecdotal interest, such as a case series of an iboga microdosing protocol in post-concussive and hypoxic brain injury[2], but this is the weakest kind of evidence and, given ibogaine’s capacity to cause fatal heart-rhythm disturbances, not a basis for use. For stroke and spinal injury specifically, there is essentially nothing.
Psilocybin and Neurological Injury
Psilocybin is the compound most associated with the hopeful, recovery-focused side of this field, and that hope is mostly mechanistic. Classic psychedelics promote neuroplasticity and reduce neuroinflammation in the laboratory, and reviews argue these properties could in principle support recovery after an acquired brain injury[1]. The human data remain observational and indirect: for example, veterans with a history of brain injury who attended psilocybin retreats reported better mental health and showed normalised resting brain activity[2].
The most concrete movement is in adjacent neurological conditions rather than in stroke or spinal injury: early trials are testing psilocybin-assisted approaches in functional neurological disorder, and a first study in persistent post-concussive symptoms is recruiting (on the TBI page). For neurological injury as a whole, psilocybin is a mechanistically attractive idea with, as yet, no controlled human evidence of benefit, and any effect is far more likely to be on mood and functioning than on the injury itself.
Ketamine and Neurological Injury
Ketamine is everywhere in neurological-injury medicine, but mostly in a role unrelated to psychedelic therapy. As a fast-acting anaesthetic that preserves breathing and blood pressure, it is widely used in the acute, intensive-care management of severe brain injury, where analyses look at its effects on physiology such as intracranial pressure and on outcomes[1], and it is even being studied as a way to improve consciousness in patients with post-comatose disorders of consciousness. This is mainstream neurocritical care.
Separately, and much more tentatively, ketamine’s rapid antidepressant effect is being explored for the mood consequences of injury, including small trials in post-stroke depression. That fits the wider pattern on this page: a plausible treatment for the psychiatric after-effects, still early and unproven. The two uses should not be conflated, the acute-care role is established; the psychedelic-style, sequelae-focused role is exploratory.
Clinical Outlook
The realistic near-term outlook is that progress in this umbrella will come almost entirely through its sub-areas, above all traumatic brain injury, rather than through "neurological injury" as a single target. The momentum from the magnesium-ibogaine work, a recruiting psilocybin trial in post-concussive symptoms, and ketamine trials in injury-related depression are the concrete steps; the broader brain-injury literature continues to make the mechanistic case[1] for stroke and other injuries, but largely from animal data.
For stroke, hypoxic injury and spinal cord injury specifically, the honest outlook is that controlled human research has barely begun, and that the exciting preclinical findings about neuroplasticity have not yet been put to a real clinical test. The most valuable developments would be unglamorous: properly controlled trials targeting well-defined after-effects (post-stroke depression, for instance) in clearly defined injury populations. Until those exist, this remains a field of strong rationale and weak evidence, and the gap should be stated plainly rather than papered over.
Industrial Landscape
The activity in this space is fragmented and early, and clusters around the sub-areas rather than the umbrella. The most organised effort is in traumatic brain injury, driven by veteran-focused researchers and advocates; elsewhere, interest comes from academic neuroscientists drawn by the neuroplasticity story and from rehabilitation researchers looking for anything that might improve recovery. There is little commercial development aimed specifically at stroke or spinal injury, partly because the evidence is so preliminary.
For an honest broker, the risk here is a particular kind of overreach: the leap from genuinely exciting laboratory findings about neuroplasticity to the implication that psychedelics can help people recover from strokes or repair spinal injuries. Nothing in the human evidence supports that yet. The responsible message is to welcome the mechanistic research and the early TBI signal, to push for the controlled trials that would test the broader promise, and to be clear with patients and families that, for neurological injury beyond a single uncontrolled study in TBI, this is hope grounded in biology, not treatment grounded in evidence.
Quick Indicators
Related Topics
Organisations
Search →University of Amsterdam
The University of Amsterdam (UvA) is one of the Netherlands' leading research universities, with its Amsterdam UMC Department of Psychiatry conducting clinical trials on psilocybin and psychedelic-assisted therapies for treatment-resistant mental health conditions.
University of California, San Francisco
University of California, San Francisco (UCSF) hosts major psychedelic research activity through the Translational Psychedelic Research Program (TrPR), Neuroscape Psychedelics Division, and psychiatry-led clinical research on psychedelic-assisted therapies.
Columbia University
Research with psychedelics has been taking place at Columbia University in New York since 2014. Researchers from various departments at the university including Medicine, Psychology and Psychiatry have conducted numerous trials investigating the effects ketamine has on substance use disorders. Some research exploring the anti-depressant effects of ketamine has also taken place. More recently, Columbia University served as a test site for COMPASS Pathway's COMP360 trial which explored the effects of psilocybin on treatment-resistant depression. Professor of Clinical Psychiatry, Dr David Hellerstein served as the principal investigator at this study site.
Usona Institute
Usona Institute is a US-based 501(c)(3) non-profit medical research organisation headquartered in Madison, Wisconsin. Usona develops and supports clinical research on psilocybin and other consciousness-expanding medicines with a mission-driven access model. Its psilocybin programme received FDA Breakthrough Therapy Designation for major depressive disorder in 2019. After completing the Phase 2 PSIL201 study, Usona launched the Phase 3 uAspire trial in 2024, a 240-participant randomised, double-blind multicentre study of 25 mg psilocybin with psychosocial support for adults with MDD. In April 2026, industry reporting said Usona confirmed it had received an FDA Commissioner National Priority Voucher for psilocybin in MDD, potentially shortening review if an NDA is filed and accepted. Usona is also exploring 5-MeO-DMT in early-stage research.
Johns Hopkins University
The Centre for Psychedelic and Consciousness Research focuses on how psychedelics affect behavior, cognition, brain function, and biological health markers. They have been at the forefront of demonstrating the safety and efficacy of psychedelics for mental disorders, expanding their focus into psilocybin research across multiple mental health conditions, including smoking cessation, major depressive disorder, and cancer-related anxiety.
Stanford University
At the Stanford School of Medicine, researchers from the Rodriguez Lab and the Heifets Lab have united under the banner of the Stanford Psychedelic Science Group. Their primary clinical focus is to investigate compounds including ketamine, psilocybin, and MDMA as potential treatments for debilitating disorders such as obsessive-compulsive disorder (OCD), treatment-resistant depression, and post-traumatic stress disorder (PTSD).
Assistance Publique Hopitaux De Marseille
Assistance Publique Hôpitaux de Marseille (AP-HM) is the public hospital authority of Marseille, France, comprising four major hospital groups and operating as one of the largest university hospital centers in Europe with extensive clinical research infrastructure. AP-HM has been involved in psychedelic medicine research through its clinical trial network, contributing to France's emerging landscape of psychiatry trials exploring psychedelic-assisted therapies.
AZ Delta
AZ Delta is a major Belgian hospital group headquartered in Roeselare, Flanders, operating four campuses with 1,403 approved beds. It participates in the multi-centre BIKe (Brain Injury and Ketamine) randomized controlled trial (NCT05097261) investigating ketamine's safety as an adjunct sedative in severe traumatic brain injury.
AZ Sint-Jan AV
AZ Sint-Jan Brugge-Oostende AV is a leading Belgian teaching hospital in Bruges with a dedicated Clinical Trial Center (CTC) that sponsors and participates in academic and commercial drug studies. Its Department of Anesthesiology and Intensive Care Medicine is a confirmed site in the BIKe (Brain Injury and Ketamine) randomized controlled trial (NCT05097261) investigating ketamine's role in severe traumatic brain injury management.
AZ Turnhout
AZ Turnhout is a general hospital in Turnhout, Antwerp province, Belgium, providing comprehensive medical and surgical care to the northern Campine region. Its Department of Anesthesiology and Intensive Care Medicine is a confirmed site in the BIKe (Brain Injury and Ketamine) randomized controlled trial (NCT05097261) investigating ketamine as an adjunct sedative in severe traumatic brain injury patients.
Beijing Tiantan Hospital
China's premier neurology and neurosurgery hospital, affiliated with Capital Medical University and home to the National Clinical Research Center for Neurological Diseases. Conducted the PASSION trial — a randomized, placebo-controlled study of intraoperative ketamine for depression in neurosurgical patients.
Brooke Army Medical Center
Brooke Army Medical Center (BAMC) at Joint Base San Antonio is the US Army's flagship medical institution and the Department of Defense's only Level I Trauma Center, and has been a primary site in multi-center randomized controlled trials investigating ketamine for antidepressant-resistant PTSD in active duty military and veterans. BAMC researchers have also contributed to pilot studies on service members' perspectives on psychedelic-assisted therapies including MDMA and psilocybin for PTSD and traumatic brain injury.
People
Search →Attila Szabo
Researcher in psychoneuroimmunology and psychedelic science; affiliated with the University of Oslo
He is a notable contributor to psychedelic immunology research, including widely cited work on DMT, 5-MeO-DMT, psilocybin, and immune modulation.
Mathieu Seynaeve
Senior Medical Director and Head of Psychotherapy at Beckley Psytech
He is a clinical development leader behind multiple human studies of 5-MeO-DMT and psilocybin, including trials in alcohol use disorder, treatment-resistant depression, and headache disorders.
Jakub Vohryzek
Postdoctoral Researcher, Computational Neuroscience Group, University Pompeu Fabra (UPF)
He is a neuroscientist contributing to high-profile psychedelic neuroimaging and whole-brain modeling studies on psilocybin, DMT, and related altered states.
Marcelo Falchi
Psychiatrist, Professor of Medicine at the Federal University of Rio Grande do Norte (UFRN), and Medical Director at the Center for Advanced Psychedelic Medicine (CAMP)
He is a Brazilian psychiatrist and psychedelic-science researcher involved in pioneering LSD and DMT clinical studies, including work on cognition, creativity, language, and inhaled DMT safety.
Fire Erowid
Co-founder and editor of Erowid Center
Fire Erowid is a key figure in psychedelic information curation and a recurring coauthor on research built from Erowid’s experience-report archives.
Jessica Maples-Keller
Associate Professor in the Emory School of Medicine, Department of Psychiatry and Behavioral Sciences; Associate Director of the Emory Healthcare Veterans Program
She is a prominent translational PTSD and psychedelic-therapy researcher contributing to MDMA and psilocybin studies, including work on fear extinction, treatment barriers, and culturally informed psychedelic-assisted therapy.
Luiz Tófoli
Professor in the Department of Psychiatry, Faculty of Medical Sciences, UNICAMP
Notable for empirical and methodological contributions to the study of ayahuasca, ibogaine and early-stage psychedelic-assisted therapies in Brazil, including survey research on adverse effects and pilot clinical work with MDMA-assisted psychotherapy.
Alan Davis
Associate Professor of Social Work & Director, Center for Psychedelic Drug Research
Noted for advancing epidemiological, naturalistic and mixed-method research on therapeutic and adverse outcomes of psychedelics and for translating those findings into clinical and harm-reduction contexts.
Sidarta Ribeiro
Professor of Neuroscience
A leading Brazilian neuroscientist who has bridged basic neurophysiology and clinical psychedelic research, contributing influential studies on ayahuasca, DMT and LSD and helping to advance psychedelic-assisted therapies in Brazil.
Nathan Sepeda
Director of Data & Analytics
Notable for his contributions to clinical and experimental studies of psilocybin-assisted interventions, including trials of major depressive disorder and investigations of enduring psychological and neurofunctional effects.
Draulio Araújo
Neuroscientist
A leading neuroimaging researcher who has produced influential clinical and physiological studies of ayahuasca and other psychedelics, linking brain dynamics to subjective experience and rapid antidepressant effects.
David Luke
Professor of Exceptional Experience
Noted for rigorous qualitative and naturalistic research into DMT and other exceptional psychedelic experiences, and for advancing study of extended difficulties, aftercare and harm reduction in psychedelic use.
Connected Evidence
The latest clinical data and verified academic findings associated with Neurological Injury.